| Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon |
2020-05-15 |
| OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader |
2020-05-15 |
| Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch |
2020-05-13 |
| Polyganics–Instinctif Partners: public relations, 202005 service existent by Instinctif |
2020-05-13 |
| Bone Therapeutics–SEVERAL: credit, 202004– bridge loans €4.75m |
2020-04-29 |
| Bone Therapeutics–SEVERAL: credit, 202004– fleixble convertibe bonds €4.99m |
2020-04-29 |
| Bone Therapeutics–SEVERAL: investment, 202004 private equity placement €1.26m in form of immediate conversion of convertible bonds |
2020-04-29 |
| Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF |
2020-04-29 |
| Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute |
2020-04-29 |
| Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK |
2020-04-29 |
| Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m |
2020-04-29 |
| Robocath–SEVERAL: investment, 202004 financing round Series C €40m led by MicroPort Scientific |
2020-04-29 |
| Genedata–Cergentis: genomic software tools, –202004 collab developm of Genedata Selector s/w for automating TLA data analysis workflow |
2020-04-28 |
| FoRx Therapeutics–Life Sciences Partners: investment, 202004 seed financing round totalling €10m incl co-investor LSP |
2020-04-22 |
| FoRx Therapeutics–Merck (DE): investment, 202004 seed financing round totalling €10m incl co-lead investor M Ventures |
2020-04-22 |
| FoRx Therapeutics–SEVERAL: investment, 202004 seed financing round €10m co-led by M Ventures + Novartis Venture Fund + Omega Funds |
2020-04-22 |
| Galapagos–Ryvu Therapeutics: anti-inflammatory drugs, 202004– collab r+d small molecules against new target w excl license option for Galapagos |
2020-04-16 |
| Centogene–FTI Consulting: public relations, 202004 service existent by FTI Consulting |
2020-04-15 |
| Gadeta–Optimum Strategic Communications: public relations, 202004 service existent by Optimum |
2020-04-07 |
| iTeos Therapeutics–6 Dimensions Capital: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor 6 Dimensions Capital |
2020-04-01 |
| iTeos Therapeutics–Belgium (govt): investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor SFPI |
2020-04-01 |
| iTeos Therapeutics–Curative Ventures: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor Curative Ventures |
2020-04-01 |
| iTeos Therapeutics–Fund+: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor Fund+ |
2020-04-01 |
| iTeos Therapeutics–HBM: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor HBM Partners |
2020-04-01 |
| iTeos Therapeutics–Invus Group: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor Invus |
2020-04-01 |
| iTeos Therapeutics–Janus Henderson: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor Janus Henderson Investors |
2020-04-01 |
| iTeos Therapeutics–MPM Capital: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor MPM Capital |
2020-04-01 |
| iTeos Therapeutics–RA Capital Management: investment, 202004 financing round Series B2 totalling $125m incl new + co-lead investor RA Capital |
2020-04-01 |
| iTeos Therapeutics–RTW Investments: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor RTW Investments |
2020-04-01 |
| iTeos Therapeutics–SEVERAL: investment, 202004 financing round Series B2 $125m co-led by RA Capital Management + Boxer Capital |
2020-04-01 |
| iTeos Therapeutics–Tavistock: investment, 202004 financing round Series B2 totalling $125m incl new + co-lead investor Boxer Capital |
2020-04-01 |
| iTeos Therapeutics–Univ Leuven: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor VIVES Louvain Technology Fund |
2020-04-01 |
| iTeos Therapeutics–Wallonia (govt): investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor SRIW |
2020-04-01 |
| Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments |
2020-03-31 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Bone Therapeutics–Image Box: public relations, 202003– supply service by Image Box PR |
2020-03-06 |
| Biotalys–Novalis LifeSciences: investment, 202003 financing round Series C 2nd closing totalling €10m incl new investor Novalis LifeSciences |
2020-03-05 |
| Biotalys–SEVERAL: investment, 202003 financing round Series C €10m 2nd closing bringing total Series C to €45m |
2020-03-05 |
| Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Thermo Fisher: investment, 202003– acquisition €9.14b cash tender offer at €39/share ANNOUNCED |
2020-03-03 |
| Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition |
2020-03-03 |
| Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition |
2020-03-03 |
| Thermo Fisher–Wachtel Lipton Rosen & Katz: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen |
2020-03-03 |
| Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m |
2020-02-21 |
| OncoDNA–Belgium (govt): investment, 202002 financing round Series B totalling €19m incl significant support from co-investor SFPI-FPIM |
2020-02-14 |
| OncoDNA–SEVERAL: investment, 202002 financing round Series B €19m co-led by Vesalius Biocapital III + Swisscanto Invest |
2020-02-14 |
| OncoDNA–Vesalius Biocapital: investment, 202002 financing round Series B totalling €19m incl co-lead investor Vesalius Biocapital III |
2020-02-14 |
| OncoDNA–Zürcher Kantonalbank: investment, 202002 financing round Series B totalling €19m incl co-lead investor Swisscanto Invest by ZKB |
2020-02-14 |
| Azafaros–BioGeneration Ventures: investment, 202002 financing round Series A totalling €25m incl existing + co-investor BiGV |
2020-02-06 |
| Azafaros–BioMedPartners: investment, 202002 financing round Series A totalling €25m incl co-investor BioMedPartners |
2020-02-06 |
| Azafaros–Forbion: investment, 202002 financing round Series A totalling €25m incl lead investor Forbion |
2020-02-06 |
| Azafaros–SEVERAL: investment, 202002 financing round Series A €25m led by Forbion with participation from BioMedPartners + BGV |
2020-02-06 |
| Azafaros–Trophic Communications: public relations, 202002 service existent by Trophic Communications |
2020-02-06 |
| Catalent–SEVERAL: investment, 202002 underwritten public offering $500m+$75m with approx $330m intented to finance MaSTherCell acquisition |
2020-02-03 |
| Orgenesis–Catalent: investment, 202002 acquisition $315m in cash of MaSTherCell Global Inc from Great Point Partners + SFPI-FPIM + Orgenesis Inc |
2020-02-03 |
| iTeos Therapeutics–Wallonia (govt): grant?, 202001 non-dilutive funding €11.5m for ph1b/2a of EOS-850 from Walloon Region |
2020-01-30 |
| iTeos Therapeutics–Wallonia (govt): grant?, 202001 non-dilutive funding €3.5m for ph1 of EOS-448 from Walloon Region |
2020-01-30 |
| iOnctura–SEVERAL: investment, 202001 financing round Series A €15m led by Inkef Capital + co-led by VI Partners |
2020-01-23 |
| PDC*line Pharma–SEVERAL: investment, 202001 financing round Series B €13.9m with existing + new investors |
2020-01-22 |
| Fibrocor Therapeutics–Galapagos: investment, 202001 equity investment by Galapagos as part of expanded collaboration |
2020-01-15 |
| Galapagos–Fibrocor Therapeutics: fibrosis drug, 202001– collab developm expansion excl license option for 4 addit small molecule inhibitor programmes |
2020-01-15 |
| Amgen–Qiagen: molecular companion diagnostics, 202002– collab developm KRAS G12C CDx for AMG 510 in NSCLC |
2020-01-13 |
| NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group |
2020-01-10 |
| NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C USD22m led by existing investors BIVF + PPF Group wih all private investors |
2020-01-10 |
| NorthSea Therapeutics–BioGeneration Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor BGV |
2020-01-08 |
| NorthSea Therapeutics–Forbion: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Forbion |
2020-01-08 |
| NorthSea Therapeutics–New Science Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor NSV |
2020-01-08 |
| NorthSea Therapeutics–Novo Group: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Novo Seeds |
2020-01-08 |
| NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio |
2020-01-08 |
| NorthSea Therapeutics–Sofinnova: investment, 202001 financing round Series B totalling €36m incl new + co-investor Sofinnova Investments |
2020-01-08 |
| NorthSea Therapeutics–VenBio: investment, 202001 financing round Series B totalling €36m incl new + lead investor VenBio Partners |
2020-01-08 |
| Wellington Partners–MC Services: public relations, 202001 service existent by MC Services |
2020-01-08 |
| FSHD Unlimited Coop–Evotec: investment, 201912 investment existent Evotec owns 21.12% of voting rights |
2019-12-31 |
| Vico Therapeutics–Kurma: investment, 2019Q4c financing round Series A totalling €20m incl investor Kurma Partners |
2019-12-31 |
| Vico Therapeutics–Life Sciences Partners: investment, 2019Q4c financing round Series A totalling €20m incl investor LSP |
2019-12-31 |
| Vico Therapeutics–SEVERAL: investment, 2019Q4c financing round Series A €20m incl LSP + Kurma Partners |
2019-12-31 |
| BioNtech–EU (govt): credit, 201912– EIB/EFSI loan €50m to support cancer therapies r+d |
2019-12-17 |
| Augustine Therapeutics–SEVERAL: investment, 201912 seed financing round €4.2m from V-Bio Ventures + PMV + Advent France + Gemma Vrisius + VIB |
2019-12-16 |
| Promethera–SEVERAL: investment, 201912 financing round Series D extension €7.5m bringing total round to €47.2m |
2019-12-16 |
| ImCheck Therapeutics–Boehringer: investment, 201912 financing round Series B totalling €48m incl existing + co-investor BIVF |
2019-12-04 |
| ImCheck Therapeutics–Eurazeo: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Idinvest Partners |
2019-12-04 |
| ImCheck Therapeutics–Gimv: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Gimv |
2019-12-04 |
| ImCheck Therapeutics–Kurma: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Kurma Partners |
2019-12-04 |
| ImCheck Therapeutics–Life Sciences Partners: investment, 201912 financing round Series B totalling €48m incl existing + co-investor LSP |
2019-12-04 |
| ImCheck Therapeutics–SEVERAL: investment, 201912 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures |
2019-12-04 |
| ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
2019-11-29 |
| LabCorp–Qiagen: bioinformatics, 201911– license extension with HGMD in addition ot Qiagen Clinical Insights |
2019-11-20 |
| Kuros–SEVERAL: investment, 201911–201912 capital increase CHF12.5m with 6.405m new registered shares at CHF1.95/share |
2019-11-19 |
| Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies |
2019-11-19 |
| Acticor Biotech–SEVERAL: investment, 201911 financing round Series B extension €7m led by new investorGO Capital bringing Series B to €22.3m |
2019-11-06 |
| Argenx–SEVERAL: investment, 201911 global offering $557m with 4.6m ordinary shares incl in the form of ADSs |
2019-11-06 |
| AVCare–Acticor Biotech: investment, 201911 acquisition 100% of AVCare by Acticor Biotech |
2019-11-06 |
| Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market |
2019-10-28 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo-2019.png){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
